Dr. Roni Tamari, MD

Dr. Tamari practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Tamari's NPI, 1689861437, was assigned on September 25, 2007. Dr. Tamari graduated from Ben Gurion University of the Negev in 2002. Dr. Tamari holds New York license 246912.

Dr. Tamari's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Tamari's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Dr. Tamari to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tamari practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tamari's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tamari is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Tamari's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists chronic anemia, chronic leukemia, multiple myeloma and neutropenia among the conditions Dr. Tamari treats.

CMS data shows 400 Medicare services from Dr. Tamari across 5 procedure codes in 2024, for 123 Medicare patients. Medicare paid $42,853 for them.

CMS counts 123 Medicare patients who saw Dr. Tamari in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 3.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tamari's median patient age at 70, with 43% women.

In 2024, Dr. Tamari wrote 1,041 Medicare Part D claims for 100 patients. 89% of them were for generic drugs. CMS names the drug for 837 of them, across 21 drugs with 11 or more claims each, at $1,169,650 in total drug cost. In 2023, CMS named 683 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Tamari for performance year 2024, reported as part of a group. Dr. Tamari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tamari as offering telehealth.

Dmand AI links 116 papers to Dr. Tamari, published from 2012 to 2025. 2021 was the busiest year, with 17. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation, Homologous and Transplantation Conditioning. Dr. Tamari has published most often in Biol Blood Marrow Transplant. Dr. Tamari's most frequent co-authors are Sergio A. Giralt, MD, Ann A. Jakubowski, MD and Esperanza Papadopoulos, MD.

Dmand AI links Dr. Tamari to 6 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Myelodysplastic Syndromes, Disease Attributes and Primary Myelofibrosis. Memorial Sloan Kettering Cancer Center sponsors the most, 3.

CMS Open Payments shows 3 general payments to Dr. Tamari from 3 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Incyte Corporation paid the most, $112.

Dr. Tamari graduated from Ben Gurion University of the Negev in 2002.

Dr. Tamari is in network with 12 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.